11/5/2026

speaker
Conference Operator
Operator

Hello, everyone. Thank you for joining us and welcome to the Innate Pharma Third Quarter 2026 Business Update and Financial Results. After today's prepared remarks, we will host a question and answer session. If you would like to ask a question, please press star 1 to raise your hand. To withdraw your question, press star 1 again. I will now hand the conference over to Stephanie Cornen, Vice President, Investor Relations, Communication and Commercial Strategy at Innate Pharma. Please go ahead.

speaker
Stephanie Cornen
Vice President, Investor Relations, Communication and Commercial Strategy

Good morning and good afternoon, everyone. Thank you for joining us for Innate Pharma's third quarter 2026 Business Update and Financial Results Conference call. The press release and today's presentation are both available on the IR section of our website. Before we begin, I would like to remind everyone that today's presentation includes forward-looking statements based on current expectations. These statements involve risks and uncertainties that would cause actual results to differ materially. To briefly cover today's agenda, our CEO, Jonathan Dickinson, will begin with a strategic overview and outlook. Marcus Jensen, our Chief Medical Officer, and Yannis Morel, our Chief Operating Officer, will then take us through updates on Lactamab, IPH4502, Monalizumab, and our preclinical ADC pipeline. Jonathan will return for our upcoming catalysts and closing remarks before we open the call for Q&A. With that, I will now hand it over to Jonathan.

speaker
Jonathan Dickinson
Chief Executive Officer

Thank you, Stephanie. Good morning to those joining from the US and good afternoon to our European participants. Turning to slide five. Since our first half update, we have continued to advance our focus portfolio while strengthening our financial position. Starting with Lekutama, the TELEMAP phase 3 study has been initiated following the closing of our strategic partnership with Sobe. with first patient dosing expected in Q1, 2027. The partnership is now effective and the 75 million upfront payment has been received. For IPH 4502, We will present Phase 1 data at the EORTC NCI AACR Symposium on November 18th, 2026. We will also host a hybrid, virtual and in-person event in London on the same day at 4pm GMT or 11am ET. Turning to Mona Luzumat, the Pacific 9 phase 3 study led by AstraZeneca is now expected to read out in the first half of 2027. Financially, our cash position as of September 30th, 2026 was 96.8 million, with an anticipated cash horizon through the end of the first quarter of 2028. Taken together, these developments position on aid for several important near-term catalysts through year-end and into 2027. Let me start with lacutamab. Lacutamab is our anti-Cur3DL2 antibody, which is being developed in cutaneous T-cell lymphoma, or CTCL. Turning to slide seven. As I mentioned, our strategic partnership with SOBI to license lacutamab in T-cell lymphoma is now effective. Telemach 3, our confirmatory phase 3 study in CTCL, has been initiated with the first patient expected in the first quarter of 2027. Enate is conducting the phase 3 study and we plan to file for accelerated approval in cesarean syndrome based on the existing phase 2 Telemach data. Upon potential accelerated approval, SOBI will receive global rights to commercialize lacuntamab. Following positive phase three results, SOBI will be eligible to obtain full global development rights. Under the terms of the agreement, we received 75 million upfront payments and are eligible for up to 40 million in near-term milestones connected to cesarean syndrome and up to an additional 465 million related to SOBI's option to obtain full development rights and future regulatory and commercial milestones. The agreement also includes tiered double-digit royalties on future net sales. I will now hand it over to Marcus, our CMO, to review the clinical and regulatory roadmap. Marcus.

Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-

Use this data in your own app

Pull this call's transcript, audio and slides with the Earnings call transcripts API.

See pricing

9,000+ companies · REST API

Investor presentation